The Frisco, TX-based company began the trial on Wednesday and said it will test the InspectIR portable breathalyzer.
"As most of us have experienced, the world has changed due to the coronavirus pandemic. We challenged our development teams with a simple question: 'Can we help?' We quickly realized our devices could identify COVID-19 in the breath and help with the unique circumstances facing the U.S. and the world right now," InspectIR CEO Tim Wing, said in a release. "It provides detection of VOCs on the breath, including COVID-19, Influenza A and more, in as little as 90 seconds. This means health professionals can almost immediately have an accurate diagnosis and begin effectively treating the patient – giving them a far better chance for a positive outcome."
One of the many challenges of facing the current COVID-19 testing is the frequency of false positives as well as false negatives, which have been reported potentially as high as 48.5%.
In a release, InspectIR COO John Redmond said, "Accuracy has been an issue with COVID-19 testing since the beginning of the crisis. Our device is specifically designed for trace detection in the high part-per-trillion. We believe it will provide the most accurate results on the market. There are few viable non-invasive detection tools available today."